Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07314333 · ClinicalTrials.gov registry record · Phase 1

A Trial to Assess How Centanafadine Interacts With Stimulants in the Body

A Phase 1 study of ADHD, sponsored by Otsuka Pharmaceutical Development & Commercialization.

Recruiting
Registry status
Phase 1
Development phase
42
Enrollment target
1
Study location

NCT07314333 is a Phase 1 study of ADHD that is actively recruiting participants, run by Otsuka Pharmaceutical Development & Commercialization. The registered enrollment target is 42 participants, below the 190-participant average among 75 other ADHD trials with a reported enrollment target (78% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07314333, a Phase 1 study of ADHD, is actively recruiting participants, sponsored by Otsuka Pharmaceutical Development & Commercialization.

RECRUITING
Registry status
Phase 1
Development phase
42 participants
Enrollment target
1
Study location

Study Summary

This study will look at how centanafadine works when taken together with stimulant medicines in healthy adults, and whether combining them affects how the body responds.

Conditions Studied

Interventions

  • DRUG Methylphenidate
  • DRUG Centanafadine
  • DRUG Lisdexamfetamine

Study Locations (1)

Utah

  • ICON - Salt Lake City

Trial Details

FieldValue
Enrollment Target 42 participants
Start Date 2026-02-05
Est. Completion 2026-04-03
Phase Phase 1

What the Registry Record Tells You About NCT07314333

The ClinicalTrials.gov registry entry for NCT07314333 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 190-participant average among 75 other ADHD trials with a reported enrollment target (78% lower). The listed sponsor is Otsuka Pharmaceutical Development & Commercialization, which has 221 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with ADHD appearing as the primary indexed condition, and to 3 interventions - of which Methylphenidate is the first listed.

NCT07314333 reports 1 study location spanning 1 distinct geographic area - top geographies include Utah.

Frequently Asked Questions

What is clinical trial NCT07314333 about?

NCT07314333 is a clinical study titled "A Trial to Assess How Centanafadine Interacts With Stimulants in the Body". This study will look at how centanafadine works when taken together with stimulant medicines in healthy adults, and whether combining them affects how the body responds.

What is the current status of trial NCT07314333?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 42 participants. The study started on 2026-02-05. Estimated completion is 2026-04-03.

What conditions does trial NCT07314333 study?

This clinical trial studies the following conditions: ADHD.

What interventions are being tested in trial NCT07314333?

The interventions under investigation include: Methylphenidate (DRUG), Centanafadine (DRUG), Lisdexamfetamine (DRUG).

Who is sponsoring clinical trial NCT07314333?

This trial is sponsored by Otsuka Pharmaceutical Development & Commercialization, which has 221 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07314333 being conducted?

This trial has 1 study location across Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for ADHD

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.